Emmanuel Raffoux

Menin inhibition with revumenib for <i>NPM1</i>-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Martha Arellano, Michael J. Thirman, John F. DiPersio et al. · Blood · 2025 · 47 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

Joshua F. Zeidner, Junichiro Yuda, Justin M. Watts et al. · Blood · 2024 · 39 citations

Pharmacy, Pharmacology, Pharmacotherapy +11

Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 ⁺ Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia

Thibaut Leguay, Marc Delord, Cyril Šálek et al. · Journal of Clinical Oncology · 2024 · 34 citations

Medicine, Hematology, Oncology +16

Early detection of <i>WT1</i> measurable residual disease identifies high-risk patients, independent of transplantation in AML

Juliette Lambert, Jérôme Lambert, Xavier Thomas et al. · Blood Advances · 2021 · 27 citations · Full text

Medicine, Hematology, Oncology +15

Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with <i>TP53</i> mutant MDS/AML

David A. Sallman, Rami S. Komrokji, Amy E. DeZern et al. · HemaSphere · 2025 · 12 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16